Revenio Group Corporation: REVENIO TO ESTABLISH A SUBSIDIARY REVENIO RESEARCH OY TO MANAGE RESEARCH AND DEVELOPMENT PROJECTS

Revenio Group Corporation Stock Exchange Release, December 1, 2014 at 11:10 am

REVENIO TO ESTABLISH A SUBSIDIARY REVENIO RESEARCH OY TO MANAGE RESEARCH AND
DEVELOPMENT PROJECTS

Revenio Group Corporation's Board of Directors has today made a decision to
establish a subsidiary Revenio Research Oy to manage the research and
development projects of Revenio Group. Revenio Research Oy will focus on the
development of the current products and on the health technology related
research and development projects that aim to discover and commercialize new
health technology related opportunities. The common nominators for these
projects are screening, monitoring and worldwide need for cost savings in health
care through preventive health care. The goal is to build growth paths from
these new openings alongside the current products of Revenio Group.

Revenio Research Oy will be attached to group reporting in connection with the
financial statement for 2014.

"Our goal is, in line with our strategy, to invest in the future growth in
health technology. During the current year we have made progress in this area
and therefore the establishment of Revenio Research Oy to manage the new
innovations is both relevant and timely. In our view, it is possible to build
interesting growth paths with the new technologies we have been able to
recognize alongside our current products", says Revenio Group's President and
CEO Olli-Pekka Salovaara.


Revenio Group Corporation
Olli-Pekka Salovaara
President & CEO


For additional information, please contact
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi


DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi


The Revenio Group in brief
Revenio is a Finnish health tech group whose core business lies in tonometers.
The Revenio Health Tech segment comprises the business operations of Icare
Finland Oy and Oscare Medical Oy. The widely patented Icare product family is
the current cornerstone of the Group's success. Revenio seeks vigorous growth in
health technology, both organically and through acquisitions and mergers.

The Revenio Group also includes other business operations, which are grouped
under the Technology and Services segment. This segment's operations have a
shared global market and represent the cutting edge of technology products and
services in their industry.

In 2013, the Revenio Group's net sales totaled EUR 25.7 million, with its
operating margin standing at 21.7%. The Revenio Group Corporation is listed on
NASDAQ OMX Helsinki.



[HUG#1875534]